691 related articles for article (PubMed ID: 28802619)
1. Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies.
Herring WJ; Woo T; Assaid CA; Lupinacci RJ; Lemmens HJ; Blobner M; Khuenl-Brady KS
J Clin Anesth; 2017 Sep; 41():84-91. PubMed ID: 28802619
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults.
Hristovska AM; Duch P; Allingstrup M; Afshari A
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012763. PubMed ID: 28806470
[TBL] [Abstract][Full Text] [Related]
3. Neuromuscular Blockade and Reversal Practice Variability in the Outpatient Setting: Insights From US Utilization Patterns.
Bash LD; Black W; Turzhitsky V; Urman RD
Anesth Analg; 2021 Dec; 133(6):1437-1450. PubMed ID: 34784330
[TBL] [Abstract][Full Text] [Related]
4. Early and late reversal of rocuronium and vecuronium with neostigmine in adults and children.
Bevan JC; Collins L; Fowler C; Kahwaji R; Rosen HD; Smith MF; de Scheepers LD; Stephenson CA; Bevan DR
Anesth Analg; 1999 Aug; 89(2):333-9. PubMed ID: 10439743
[TBL] [Abstract][Full Text] [Related]
5. A Clinical and Budgetary Impact Analysis of Introducing Sugammadex for Routine Reversal of Neuromuscular Blockade in a Hypothetical Cohort in the US.
Jiang Y; Bash LD; Saager L
Adv Ther; 2021 May; 38(5):2689-2708. PubMed ID: 33871823
[TBL] [Abstract][Full Text] [Related]
6. Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results from a phase IV randomized study.
Voss T; Wang A; DeAngelis M; Speek M; Saldien V; Hammer GB; Wrishko R; Herring WJ
Paediatr Anaesth; 2022 Mar; 32(3):436-445. PubMed ID: 34878707
[TBL] [Abstract][Full Text] [Related]
7. Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a randomized clinical trial.
Horrow JC; Li W; Blobner M; Lombard J; Speek M; DeAngelis M; Herring WJ
BMC Anesthesiol; 2021 Feb; 21(1):62. PubMed ID: 33639839
[TBL] [Abstract][Full Text] [Related]
8. Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical Settings.
Bash LD; Turzhitsky V; Black W; Urman RD
Adv Ther; 2021 Sep; 38(9):4736-4755. PubMed ID: 34319550
[TBL] [Abstract][Full Text] [Related]
9. Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Block in Patients Having Catheter-Based Neurointerventional Procedures: A Randomized Trial.
Farag E; Rivas E; Bravo M; Hussain S; Argalious M; Khanna S; Seif J; Pu X; Mao G; Bain M; Elgabaly M; Esa WAS; Sessler DI
Anesth Analg; 2021 Jun; 132(6):1666-1676. PubMed ID: 34032663
[TBL] [Abstract][Full Text] [Related]
10. Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade in Patients With Severe Renal Impairment: A Randomized, Double-Blinded Study.
Oh MW; Mohapatra SG; Pak T; Hermawan A; Chen CA; Thota B; Chen J; Siu E; Park J; Moon TS
Anesth Analg; 2024 May; 138(5):1043-1051. PubMed ID: 38190344
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Reversal of Neuromuscular Block in Older Adults: Sugammadex or Neostigmine.
Togioka BM; Schenning KJ
Drugs Aging; 2022 Oct; 39(10):749-761. PubMed ID: 35934764
[TBL] [Abstract][Full Text] [Related]
12. Recurarization with magnesium sulfate administered after two minutes sugammadex reversal: A randomized, double-blind, controlled trial.
Germano-Filho PA; Cavalcanti IL; Micuci AJQR; Velarde LGC; de Boer HD; Verçosa N
J Clin Anesth; 2023 Oct; 89():111186. PubMed ID: 37393856
[TBL] [Abstract][Full Text] [Related]
13. Comparison of recovery after sugammadex or neostigmine reversal of rocuronium in geriatric patients undergoing spine surgery: a randomized controlled trial.
Mraovic B; Timko NJ; Choma TJ
Croat Med J; 2021 Dec; 62(6):606-613. PubMed ID: 34981693
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a Protocol for the Management of Maintenance and Reversal of Rocuronium Block Using Neostigmine or Sugammadex.
Thilen SR; Liang T; Kruse TN; Cain KC; Treggiari MM; Bhananker SM
Anesth Analg; 2023 Jun; 136(6):1143-1153. PubMed ID: 37205804
[TBL] [Abstract][Full Text] [Related]
15. The Nonirritating Concentrations of Neuromuscular Blocking Agents and Related Compounds.
Gonzalez-Estrada A; Carrillo-Martin I; Morgenstern-Kaplan D; Garzon-Siatoya WT; Renew JR; Hernandez-Torres V; Volcheck GW
J Allergy Clin Immunol Pract; 2023 Feb; 11(2):466-473.e5. PubMed ID: 36108924
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the factors contributing to residual weakness after sugammadex administration in pediatric patients under 2 years of age.
Cates AC; Freundlich RE; Clifton JC; Lorinc AN
Paediatr Anaesth; 2024 Jan; 34(1):28-34. PubMed ID: 37792601
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Sugammadex for the Reversal of Rocuronium-Induced Neuromuscular Blockade in Patients with End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
Kim YS; Lim BG; Won YJ; Oh SK; Oh JS; Cho SA
Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833477
[No Abstract] [Full Text] [Related]
18. Reversal of rocuronium-induced intense neuromuscular blockade by sugammadex in Korean children: A pharmacokinetic and pharmacodynamic analysis.
Ji SH; Huh KY; Oh J; Jeong HJ; Jang YE; Kim EH; Lee JH; Kim JT; Kim HS
Clin Transl Sci; 2023 Jan; 16(1):92-103. PubMed ID: 36181377
[TBL] [Abstract][Full Text] [Related]
19. Sugammadex for reversal of moderate-to-deep rocuronium block in a clinical setting: A retrospective report of 10 dogs.
Martin-Flores M
Vet Anaesth Analg; 2024 Jan; 51(1):60-63. PubMed ID: 38072747
[TBL] [Abstract][Full Text] [Related]
20. Reversal of rocuronium induced neuromuscular block with sugammadex in patients under 2 years of age. A series of 280 cases.
Ozmete O; Dardag E; Civi S
Ann Ital Chir; 2023; 94():612-616. PubMed ID: 38131376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
